DSIP
Historical sleep-research peptide — not FDA-approved.
What it's for
DSIP (delta sleep-inducing peptide) is a nonapeptide first described in sleep research decades ago.
What it does for the body
It was investigated for sleep promotion and stress-related endpoints. It never became an FDA-approved hypnotic. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Proposed actions involved gentle adjustment of sleep architecture and hypothalamic-pituitary stress axes in experimental models; human results were inconsistent. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: DSIP is best treated as a research-interest topic. Early papers can be fascinating; they are not a green light for self-experimentation.
Studied for (literature interest)
- Brain research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: DSIP — FDA.gov search
- ClinicalTrials.gov search: DSIP — U.S. clinical trials registry
- Drugs@FDA search: DSIP — FDA drug database (if approved)
- PubMed search: DSIP — NCBI PubMed
- PubMed Central search: DSIP — NCBI PMC
Reference
No ref on file.